PURPOSE: Obstructive sleep apnea syndrome (OSAS) is common in adult population and it is associated with increased morbidity and mortality, especially due to cardiovascular disease (CVD). Both diagnosis, based on polysomnography, and treatment with continuous positive airway pressure (CPAP), carry a potentially high cost. The present study aims to analyze the cost-effectiveness of CPAP treatment versus no treatment, in the long-term, as it examines the effect of this treatment on the incidence of CVD. METHODS: A Markov model was constructed to observe the disease evolution in patients with OSAS based on published evidence. Data on treatment costs were collected from public hospitals in Greece. Within each cycle of the model, each patient may remain free of CVD, may develop CVD, may die due to a cause related to CVD, or may die from other causes. The model begins at the age of 55 years in a severe OSAS patient (apnea-hypopnea index ≥30/h) and lasts for 45 years. RESULTS: Within the limitation of the model, CPAP was found to be a cost-effective strategy versus no treatment, due to the reduction of the cost for the CVD treatment, when the analysis was restricted to the male population. Moreover, CPAP was found to be clinically more effective than no treatment, as it increases life expectancy in both males and females. CONCLUSIONS: CPAP was found to be clinically more effective therapy than no treatment in relation to CVD and a cost-effective strategy in males with severe OSAS.
PURPOSE:Obstructive sleep apnea syndrome (OSAS) is common in adult population and it is associated with increased morbidity and mortality, especially due to cardiovascular disease (CVD). Both diagnosis, based on polysomnography, and treatment with continuous positive airway pressure (CPAP), carry a potentially high cost. The present study aims to analyze the cost-effectiveness of CPAP treatment versus no treatment, in the long-term, as it examines the effect of this treatment on the incidence of CVD. METHODS: A Markov model was constructed to observe the disease evolution in patients with OSAS based on published evidence. Data on treatment costs were collected from public hospitals in Greece. Within each cycle of the model, each patient may remain free of CVD, may develop CVD, may die due to a cause related to CVD, or may die from other causes. The model begins at the age of 55 years in a severe OSAS patient (apnea-hypopnea index ≥30/h) and lasts for 45 years. RESULTS: Within the limitation of the model, CPAP was found to be a cost-effective strategy versus no treatment, due to the reduction of the cost for the CVD treatment, when the analysis was restricted to the male population. Moreover, CPAP was found to be clinically more effective than no treatment, as it increases life expectancy in both males and females. CONCLUSIONS: CPAP was found to be clinically more effective therapy than no treatment in relation to CVD and a cost-effective strategy in males with severe OSAS.
Authors: Yüksel Peker; Jan Hedner; Jeanette Norum; Holger Kraiczi; Jan Carlson Journal: Am J Respir Crit Care Med Date: 2002-07-15 Impact factor: 21.405
Authors: I Fietze; T Penzel; A Alonderis; F Barbe; M R Bonsignore; P Calverly; W De Backer; K Diefenbach; V Donic; M M Eijsvogel; K A Franklin; T Gislason; L Grote; J Hedner; P Jennum; L Lavie; P Lavie; P Levy; C Lombardi; W Mallin; O Marrone; J M Montserrat; E S Papathanasiou; G Parati; R Plywaczewski; M Pretl; R L Riha; D Rodenstein; T Saaresranta; R Schulz; P Sliwinski; P Steiropoulos; J Svaza; Z Tomori; P Tonnesen; G Varoneckas; J Verbraecken; J Vesely; A Vitols; J Zielinski; W T McNicholas Journal: Sleep Med Date: 2010-12-16 Impact factor: 3.492
Authors: Daniela V Pachito; Ângela M Bagattini; Luciano F Drager; Alan L Eckeli; Aline Rocha Journal: Sleep Breath Date: 2021-03-31 Impact factor: 2.816
Authors: Rebecca Robbins; Azizi Seixas; Girardin Jean-Louis; Sairam Parthasarathy; David M Rapoport; Gbenga Ogedegbe; Joseph A Ladapo Journal: PLoS One Date: 2018-05-23 Impact factor: 3.240
Authors: Fanny Bertelli; Carey Meredith Suehs; Jean Pierre Mallet; Marie Caroline Rotty; Jean Louis Pepin; Frédéric Gagnadoux; Eric Matzner-Lober; A Bourdin; Nicolas Molinari; Dany Jaffuel Journal: BMJ Open Date: 2021-05-10 Impact factor: 2.692